Precision Biosensor

Precision Biosensor FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Precision Biosensor (335810.KQ) as of Oct 28, 2026 is 16.66 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 20.66 % — a change of -19.33% (lower).

FCF Conversion

16.66 %

YoY

-19.33%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Precision Biosensor is 2025 16.66 % . FCF Conversion Rate (FCF/EBITDA) of Precision Biosensor was 2024 20.66 % . It decreases by -19.33% lower compared to the previous year.

The Precision Biosensor FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
80.68 KRW
Jan 1, 2019
565.70 KRW
Jan 1, 2020
140.33 KRW
Jan 1, 2021
330.57 KRW
Jan 1, 2022
201.57 KRW
Jan 1, 2023
200.56 KRW
Jan 1, 2024
20.66 KRW
Jan 1, 2025
16.66 KRW
The Precision Biosensor FCF Conversion history
YEARFCF ConversionYoY
16.66 %-19.33%
20.66 %-89.70%
200.56 %-0.50%
201.57 %-39.02%
330.57 %+135.57%
140.33 %-75.19%
565.70 %+601.18%
80.68 %-40.50%
135.60 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Precision Biosensor Stock analysis

What does Precision Biosensor do? Precision Biosensor Inc. generates revenue through the sale of portable immunoassay diagnostic devices and cartridges. The testers, which are portable devices using colorimetric and time-resolved fluorescence, are sold for on-site diagnosis of acute heart disease, metabolism, and inflammatory diseases. The cartridges, designed for gold absorption and time-resolved fluorescence analysis, are used in diagnostic equipment to check the same conditions. The company targets domestic and overseas markets including Europe, China, the Middle East, and Southeast Asia for its products. The firm's primary customers are healthcare providers and diagnostic laboratories seeking rapid, on-site testing solutions. These segments value the portability and speed of the testers, which enable immediate diagnosis without laboratory processing. The cartridges complement the testers by providing consumable components for consistent diagnostic accuracy across various medical conditions. Precision Biosensor Inc. focuses on markets where demand for point-of-care diagnostics is growing, particularly in regions with expanding healthcare infrastructure. The company's product line addresses acute heart disease, metabolism, and inflammatory diseases, aligning with global health priorities. Sales in Europe, China, the Middle East, and Southeast Asia reflect the company's strategy to serve both developed and emerging healthcare systems. Precision Biosensor is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Precision Biosensor stock

FCF Conversion Rate (FCF/EBITDA) of Precision Biosensor is 16.66 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Precision Biosensor changed from 20.66 % to 16.66 %, representing a -19.33% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Precision Biosensor since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Precision Biosensor with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Precision Biosensor

All Key Metrics — Precision Biosensor